NCT02365597 2026-04-13
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
Janssen Research & Development, LLC
Phase 2 Active not recruiting
Janssen Research & Development, LLC
AstraZeneca
Hoffmann-La Roche
PMV Pharmaceuticals, Inc
Genentech, Inc.
Turning Point Therapeutics, Inc.
Jiangsu HengRui Medicine Co., Ltd.
Health Clinics Limited
Ozmosis Research Inc.
Jiangsu HengRui Medicine Co., Ltd.
Clinique Ovo
GlaxoSmithKline
Biocinese